1.
Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence
by van Ingen, Jakko
Expert review of anti-infective therapy, 2013, Vol.11 (10), p.1065-1077
2.
THE SECRET LIVES OF THE PATHOGENIC MYCOBACTERIA
by Cosma, Christine L
Annual review of microbiology, 2003, Vol.57 (1), p.641-676
3.
Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort
by Zweijpfenning, Sanne
Respiratory medicine, 2017, Vol.131, p.220-224
4.
Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519955 migrants screened before entry to England, Wales, and Nort...
by Aldridge, Robert W
The Lancet (British edition), 2016, Vol.388 (10059), p.2510-2518
5.
S39Risk of NTM (non tuberculous mycobacterium) infection in patients on long term prophylactic macrolide antibiotics
by Adizie, J B
Thorax, 2016, Vol.71 (Suppl 3), p.A24-A25
6.
P115Screening outcomes of household contacts of multidrug-resistant tuberculosis patients in peshawar, pakistan
by Javid, A
Thorax, 2016, Vol.71 (Suppl 3), p.A145-A146
7.
P111Older patients with tuberculosis have less typical changes on chest radiographs
by Abbara, A
Thorax, 2016, Vol.71 (Suppl 3), p.A143-A143
8.
S89The use of tuberculosis chemoprophylaxis in patients of renal replacement therapy
by Ahern, N
Thorax, 2016, Vol.71 (Suppl 3), p.A51-A51
9.
P118How do foreign-born patients with tuberculosis access healthcare? a cohort analysis of referrals from general practice and the emergency department to a tertiary tuberculosis s...
by Conway, S
Thorax, 2016, Vol.71 (Suppl 3), p.A147-A147
10.
S90The nature and duration of symptoms and time to starting treatment comparing older with younger pulmonary tuberculosis patients
by Abbara, A
Thorax, 2016, Vol.71 (Suppl 3), p.A51-A52
11.
M17Limited value of baseline chest radiography in adults with non-tuberculous mycobacteria
by Murphy, ME
Thorax, 2016, Vol.71 (Suppl 3), p.A266-A267
12.
P114Implications of NICE 2016 tuberculosis guidance for a TB contact screening service
by Ray, A M
Thorax, 2016, Vol.71 (Suppl 3), p.A145-A145
13.
P116Multidrug-resistant tuberculosis (MDR-TB) monitoring in southeast london using current recommendations; does it prevent complications?
by Bradley, B
Thorax, 2016, Vol.71 (Suppl 3), p.A146-A146
14.
P112Serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis
by Ritchie, A
Thorax, 2016, Vol.71 (Suppl 3), p.A143-A143
15.
P113Indeterminate IGRA results prior to anti-tnf therapy: stable state testing may be important for immune-mediated inflammatory disorders
by Ibrahim, W
Thorax, 2016, Vol.71 (Suppl 3), p.A144-A145
16.
S113High-dose vitamin D3 during intensive phase treatment of pulmonary tuberculosis in mongolia: a double-blind randomised controlled trial
by Ganmaa, D
Thorax, 2016, Vol.71 (Suppl 3), p.A67-A68
17.
Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study
by Bryant, Josephine M, BSc
The Lancet (British edition), 2013, Vol.381 (9877), p.1551-1560
18.
Differential diagnostic assays for discriminating mycobacteria, especially for nontuberculous mycobacteria: what does the future hold?
by Hoshino, Yoshihiko
Future microbiology, 2015, Vol.10 (2), p.205-216
19.
Lung Disease Due to the More Common Nontuberculous Mycobacteria
by Field, Stephen K
Chest, 2006, Vol.129 (6), p.1653-1672
20.
Analysis of discrepant results between the Genotype registered MTBDRplus assay and an antimicrobial drug susceptibility test for isoniazid-resistant tuberculosis
by Jo, Kyung-Wook
Respiratory medicine, 2017, Vol.122, p.12-17
